1
项与 锕[225Ac]-PSMA-62 相关的临床试验[Ac-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, Tolerability, and Dosimetry in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (ACCEL)
ACCEL is a multicenter, open label phase Ia/Ib/II study of [Ac-225]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.
100 项与 锕[225Ac]-PSMA-62 相关的临床结果
100 项与 锕[225Ac]-PSMA-62 相关的转化医学
100 项与 锕[225Ac]-PSMA-62 相关的专利(医药)
100 项与 锕[225Ac]-PSMA-62 相关的药物交易